Researchers have long been interested in whether macrolides, particularly azithromycin, could lower the risk of chronic lung disease in preterm infants. This question is especially relevant for infants colonised with pulmonary Ureaplasma spp. Given the conflicting evidence from past studies, a recent rigorous trial aimed to shed light on this issue. Conducted in 30 neonatal care centers, the study’s well-defined methodology provided a robust framework to explore azithromycin’s effectiveness in this vulnerable population. Importantly, the trial addressed gaps in previous research by incorporating a sufficient sample size and controlling for variables such as gestational age.
Methodology Overview
The trial examined 796 infants born before 30 weeks of gestation who required respiratory support within the first 72 hours after birth. Participants were randomly divided into two groups: one received azithromycin, while the other received a placebo. The primary objective was to determine whether azithromycin improved survival rates without the progression to moderate or severe chronic lung disease by the infants’ 36-week postmenstrual age. Secondary outcomes scrutinised various health aspects, including the severity of chronic lung diseases and the presence of Ureaplasma spp. colonisation.
Key Findings and Data Analysis
The results revealed that 42.1% of azithromycin-treated infants and 44.5% of those in the placebo group survived without developing severe lung disease. There was no statistically significant difference between the two groups in most secondary outcomes. However, one notable exception was the lower incidence of treated retinopathy of prematurity in the azithromycin group (3.5% vs. 7.4%). Significantly, the study found no notable influence of Ureaplasma spp. colonisation on treatment efficacy.
– Infants receiving azithromycin did not exhibit improved survival without moderate or severe lung disease compared to the placebo group.
– A lower rate of retinopathy of prematurity was observed among azithromycin-treated infants.
– The data showed an increase in certain macrolide-resistance genes among azithromycin-treated infants, suggesting potential resistance development.
Current evidence does not recommend using azithromycin as prophylaxis for chronic lung disease in preterm infants, regardless of Ureaplasma spp. colonisation. The increase in macrolide-resistance genes in azithromycin-treated infants highlights the need for careful antibiotic use, given the vulnerability of this infant group to multiresistant bacteria. Future research should focus on longer-term follow-up and assessing the impact of treatment on proinflammatory cytokine levels, providing more clarity to clinical practices. The investigation into whether such treatment altered cytokine concentrations could offer further insights into how different colonisation statuses influence treatment outcomes. This research underscores the importance of judicious antibiotic use in neonatal care to mitigate the risk of antibiotic resistance while ensuring the effective management of preterm infant health conditions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
